Discover your next big idea for life sciences at PACK EXPO Las Vegas
Experience a breakthrough in life sciences packaging—explore solutions from 2,300 suppliers spanning all industries, all in one place this September

FDA Ignores Petitions, Stays Course on Abortion Pills

Petitions from both pro and anti-abortion groups were denied by the FDA’s Center for Drug Evaluation and Research.

Screen Shot 2022 04 18 At 2 47 13 Pm
Getty Images

According to an article from The Hill, the FDA has denied two citizen petitions pertaining to access to mifepristone, aka the abortion pill. Petitions came from both sides of the aisle, including a conservative group looking to restrict the drug’s use as well as a medical group looking to extend its use for a new indication. The agency’s denial means it will maintain its stance on abortion pills. First approved in 2000, mifepristone is used in combination with misoprostol during the first 10 weeks of pregnancy for termination. 

FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
FDA warning letters surge - is your team prepared?
Pharmaceutical Innovations Report
Discover the latest breakthrough packaging technologies shaping the pharmaceutical sector. This report dives into cutting-edge innovations, from smart containers that enhance patient safety to eco-friendly materials poised to transform the industry’s sustainability practices. All from PACK EXPO. Learn how forward-thinking strategies are driving efficiency and redefining what’s possible in pharma packaging.
Learn More
Pharmaceutical Innovations Report